Practice of Dapagliflozin Application in Patients with Type 2 Diabetes Mellitus

L.V. Shkala, Ya.I. Kleban, O.V. Cherpak, O.V. Shkala, O.A. Karapetian, T.H. Volkovska

Abstract


The article presents the results of using new antihyperglycemic drug — a selective inhibitor of the sodium-glucose cotransporter type 2 — dapagliflozin in patients with type 2 diabetes mellitus. The influence of this drug on the effectiveness of glycemic control, blood pressure level, lipid profile, body weight has been analyzed, compliance has been assessed. According to the practice of dapagliflozin application in the combination antidiabetic therapy, the drug is easy to use, provides sufficient glycemic control (significant decrease in glycated hemoglobin by an average of 0.98 %), reduces body weight in the presence of obesity or overweight (a decrease in the body mass index by an average of 1.78 kg/m2), has a positive effect on blood pressure, has no significant effect on the correction of dyslipidemia in the presence of transient adverse reactions in some women in the form of cystitis and vulvovaginitis, does not require discontinuation of treatment. Application of dapagliflozin in combination hypoglycemic therapy in patients with diabetes type 2 is suitable for achieving compensation.


Keywords


type 2 diabetes mellitus; dapagliflozin; efficiency

References


Инструкция по медицинскому применению препарата Форксига, утвержденная МЗ Украины 23.12.2013.

Маньковский Б.Н. Терапия сахарного диабета 2 типа: нереализованные потребности и новые возможности // Діабет. Ожиріння. Метаболічний синдром. — 2014. — № 4(ІІІ). — С. 37-41.

Филиппова И. Прогностическое значение ранней диагностики сахарного диабета // Ремедиум. — 2014. — № 3. — С. 65-75.

De Fronzo R.A. Banting Lecture. From the triumvirate to the ominous octet: A new paradigm for the treatment of type 2 diabetes mellitus // Diabetes. — 2009. — Vol. 58. — P. 773-795.

Han S., Hagan D.L., Taylor J.R. et al. Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats // Diabetes. — 2008. — Vol. 57. — P. 1723-1729.

International Diabetes Federation. IDF Diabetes Atlas. — 6th ed. — Brussels, Bergium: International Diabetes Federation, 2013. — http: idf.org/ diaberesatlas

Komoroski B., Vachharajani N., Boulton D. et al. Dapagliflozin, a novel SGLT2 inhibitor, induces dose-deendent glucosuria in healthy subjects // Clin. Pharmacol. Ther. — 2009. — Vol. 85. — P. 520-526.

Macdonald F.R., Peel J.E., Jones H.B. et al. The novel sodium glucose transporter 2 inhibitor dapagliflozin sustains pancreatic function and preserves islet morphology in obese, diabetic rats // Diabetes Obes. Metab. — 2010. — Vol. 12. — P. 1004-1012.

Meng W., Ellsworth B.A., Nirschl A.A. et al. Discovery of dapagliflozin: a potent, selective renalsodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatmentof type 2 diabetes // J. Med. Chem. — 2008. — Vol. 51. — P. 1145-1149.

Obermeier M., Yao M., Khanna A. et al. In vitro characterization and pharmacokinetics of dapagliflozin (BMS-512148), a potent sodium-glucose cotransporter type II inhibitor, in animals and humans // Drug Metab. Dispos. — 2010. — Vol. 38. — P. 405-414.

Shah N.K., Deeb W.E., Choksi R., Epstein B.J. Dapagliflozin: a novel sodium-glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus // Pharmacotherapy. — 2012. — Vol. 32(1). — P. 80-94.

Zhang L., Feng Y., List J. et al. Dapagliflozin treatment in patients with differentstages of type 2 diabetes mellitus: effects on glycaemic control and body weight // Diabetes Obes. Metab. — 2010. — Vol. 12. — P. 510-516.




DOI: https://doi.org/10.22141/2224-0721.5.69.2015.75180

Refbacks

  • There are currently no refbacks.


Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

 

© "Publishing House "Zaslavsky", 1997-2017

 

 Яндекс.МетрикаSeo анализ сайта Рейтинг@Mail.ru